Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993406 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
A Phase 3 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 13,970
- Enrollment target
NCT02993406: Completed Phase 3 study, sponsored by Esperion Therapeutics.
NCT02993406 is a Phase 3 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 13,970 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1712% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02993406, a Phase 3 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13,970 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.
Primary Outcome
The primary efficacy end point was a four-component composite of adjudicated MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, as assessed in a time-to first-event analysis.
Interventions
- DRUG Bempedoic acid 180 mg tablet
- DRUG Matching placebo tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,970 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2022-11-07 |
| Phase | Phase 3 |
What the finished NCT02993406 record still lists
NCT02993406 is an interventional study that assigns participants to a tested intervention. Its 13,970 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1712% higher).
The record links to 0 conditions, and to 2 interventions - of which Bempedoic acid 180 mg tablet is the first listed.
NCT02993406 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02993406 about?
NCT02993406 is a clinical study titled "Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo". The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.
What is the current status of trial NCT02993406?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13,970 participants. The study started on 2016-12-22. Estimated completion is 2022-11-07.
What interventions are being tested in trial NCT02993406?
The interventions under investigation include: Bempedoic acid 180 mg tablet (DRUG), Matching placebo tablet (DRUG).
Who is sponsoring clinical trial NCT02993406?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02993406's enrollment target sits among peer trials
13,970 17th of 2000 higher than 1,984 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT05141396 · 13,400 participants · NA
Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI